10-Q: KalVista Launches Oral HAE Therapy EKTERLY After FDA Approval

KalVista Pharmaceuticals reports its first product revenue following the FDA approval and commercial launch of EKTERLY, an oral on-demand therapy for hereditary angioedema.

Summary

• The U.S. Food and Drug Administration (FDA) approved EKTERLY (sebetralstat) on July 3, 2025, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
• EKTERLY is the first and only oral, on-demand therapy for HAE, based on data from the Phase 3 KONFIDENT clinical trial.
• Generated first product revenue, net, of $1.4 million for the three months ended July 31, 2025, compared to zero in the prior year period.
• Net loss increased to $60.1 million for the three months ended July 31, 2025, from $40.4 million for the same period in 2024.
• Selling, general and administrative expenses significantly increased by $27.1 million to $44.7 million, primarily due to commercialization efforts for EKTERLY.
• Received a $22.0 million milestone payment from DRI Healthcare Acquisitions LP in July 2025 due to the early FDA approval of sebetralstat, which increased the first-tier royalty rate on net sales from 5.00% to 6.00%.
• The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom granted marketing authorization for EKTERLY, with 10 years of market exclusivity.
• The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending market authorization for sebetralstat, with a final European Commission (EC) decision expected in October 2025, and maintained orphan designation for 10 years of market exclusivity.
• Granted Pendopharm exclusive rights to manage regulatory approval and commercialization of sebetralstat in Canada.
• Entered into a License, Supply and Distribution Agreement with Kaken Pharmaceutical Co., Ltd. for Japan, receiving an $11.0 million non-refundable upfront payment.
• Cash, cash equivalents, and marketable securities totaled $191.5 million as of July 31, 2025.
• The company changed its fiscal year end from April 30 to December 31, effective December 31, 2025, resulting in an eight-month transition period.

Sentiment

Score: 8

Explanation: The FDA approval of EKTERLY, coupled with positive regulatory opinions in Europe and the UK, and the first product revenue, represents a transformative period for KalVista. These achievements significantly de-risk the commercialization pathway for their lead product. However, the substantial increase in net loss and SG&A expenses reflects the high cost of commercialization, which will require careful management and potential future capital raises, despite current liquidity.

Positives

• FDA approval of EKTERLY (sebetralstat) on July 3, 2025, as the first and only oral, on-demand therapy for HAE, addressing a significant unmet medical need.
• Generated first product revenue of $1.4 million for the three months ended July 31, 2025, marking a significant commercial milestone.
• Successful Phase 3 KONFIDENT clinical trial results, published in the New England Journal of Medicine, demonstrated significantly faster symptom relief (median 1.79 hours vs. 6.72 hours for placebo) and a favorable safety profile.
• Received a $22.0 million milestone payment from DRI Healthcare Acquisitions LP due to the early FDA approval of EKTERLY.
• Secured marketing authorization from MHRA (UK) for EKTERLY, including 10 years of market exclusivity.
• Received a positive opinion from CHMP (EMA) for market authorization in Europe and maintained orphan designation, providing 10 years of market exclusivity in the EU.
• Established strategic partnerships for commercialization in Canada (Pendopharm) and Japan (Kaken Pharmaceutical Co., Ltd.), including an $11.0 million upfront payment from Kaken.
• Anticipates sufficient funding to operate for at least the next twelve months based on current operating plans and existing capital resources.

Negatives

• Net loss increased to $60.1 million for the three months ended July 31, 2025, compared to $40.4 million in the prior year period, driven by increased commercialization expenses.
• Selling, general and administrative expenses surged by $27.1 million to $44.7 million, reflecting the high costs associated with the commercial launch of EKTERLY.
• Accumulated deficit reached $713.3 million as of July 31, 2025, indicating continued historical operating losses.
• The $22.0 million milestone payment from DRI resulted in an increase in the first-tier royalty rate on net sales from 5.00% to 6.00%, increasing future obligations.
• Interest expense related to the royalty agreement increased to $3.5 million for the three months ended July 31, 2025.
• Cash and cash equivalents decreased from $131.6 million to $124.3 million, and marketable securities decreased from $89.0 million to $67.2 million from April 30, 2025, to July 31, 2025.

Risks

• Anticipates continued operating losses for the foreseeable future, expecting them to increase with EKTERLY commercialization and post-approval regulatory obligations.
• Subject to risks and uncertainties common to pharmaceutical companies with development and commercial operations, including unforeseen expenses, difficulties, complications, and delays.
• Actual financial results may materially differ from management's estimates and assumptions used in financial statements.
• The interest rate on the royalty liability may vary depending on forecasted net sales, with significant changes potentially impacting the liability, interest expense, and repayment period.
• The fair value measurement of the derivative liability is sensitive to changes in unobservable inputs, which could result in changes to its fair value.
• No material changes to the risk factors described in the Annual Report on Form 10-K, which include macroeconomic conditions, inflation, interest rates, labor shortages, supply chain issues, and global conflicts.

Future Outlook

Anticipates continued operating losses for the foreseeable future, expecting them to increase as EKTERLY commercialization begins, post-approval regulatory obligations are completed, and development of additional product candidates continues. The company expects to incur substantial operating losses even as it generates revenue from EKTERLY or its other products. Future cash needs may be financed through equity offerings, debt financing, corporate partnerships, and product sales. The company anticipates sufficient funding to operate for at least the next twelve months based on its operating plans and existing capital resources. Selling, general and administrative expenses are expected to continue at or above current levels to support EKTERLY commercialization, while research and development expenses are anticipated to remain approximately at current levels due to ongoing clinical trials (KONFIDENT-S and KONFIDENT-KID) and preclinical research. The European Commission (EC) final decision on market authorization for sebetralstat is expected in October 2025.

Management Comments

• "We are a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs."
• "EKTERLY (sebetralstat) is the first and only oral, on-demand therapy for HAE."
• "We believe that EKTERLY has the potential to fundamentally shift the manner in which HAE is managed, based upon extensive and continuing research conducted with patients, physicians and payers."
• "Our working capital, primarily cash and marketable securities, is anticipated to fund our operations for at least the next twelve months from the date these unaudited interim condensed consolidated financial statements are issued."

Industry Context

The approval of EKTERLY as the first and only oral, on-demand therapy for HAE represents a significant advancement in the treatment landscape for this rare disease. Previously, all on-demand options required intravenous or subcutaneous administration, which imposed a substantial treatment burden. This oral formulation addresses a critical unmet need, potentially shifting patient preference and market share from injectable competitors. The maintenance of orphan drug designation in the EU and UK provides significant market exclusivity, reinforcing its competitive position against other HAE treatments.

Comparison to Industry Standards

• The approval of an oral, on-demand therapy for HAE, such as EKTERLY, sets a new standard in patient convenience compared to existing injectable on-demand treatments like Takhzyro (lanadelumab) by Takeda, Haegarda (C1 Esterase Inhibitor, Human) by CSL Behring, or Firazyr (icatibant) by Shire (now Takeda).
• While injectable therapies are effective, EKTERLY's oral administration significantly reduces treatment burden, a key differentiator in patient quality of life.
• The Phase 3 KONFIDENT trial's median time to symptom relief of 1.79 hours for EKTERLY compares favorably to the onset of action for some injectable therapies, further solidifying its competitive profile.
• The 10 years of market exclusivity granted by orphan designation in the EU and UK aligns with typical protections for innovative rare disease therapies, providing a strong competitive moat.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from FDA approval and market expansion, but diluted by increased losses and potential future equity offerings.
• Patients (HAE): Significant positive impact with the availability of the first oral, on-demand treatment option, reducing treatment burden.
• Employees: Increased commercialization activities likely lead to hiring and expansion, but continued operating losses could pose long-term uncertainty.
• DRI Healthcare Acquisitions LP: Received a $22.0 million milestone payment, and will receive higher royalty rates on future sales.
• Kaken Pharmaceutical Co., Ltd.: Gained exclusive commercialization rights in Japan for sebetralstat.
• Pendopharm: Gained exclusive commercialization rights in Canada for sebetralstat.

Next Steps

• Commercialization of EKTERLY in the U.S.
• Completion of post-approval regulatory obligations for EKTERLY.
• Continued development of potential additional product candidates.
• European Commission (EC) final decision on market authorization for sebetralstat (expected October 2025).
• Ongoing KONFIDENT-S and KONFIDENT-KID clinical trials.
• Continued preclinical research, including the oral Factor XIIa inhibitor program.
• Potential offering and selling of up to $100.0 million in ATM Shares.

Key Dates

Recommendation

The FDA approval of EKTERLY as the first oral, on-demand HAE therapy is a monumental achievement, significantly de-risking the product's commercial potential. Coupled with positive regulatory momentum in Europe and the UK, and strategic partnerships in Japan and Canada, the company is poised for substantial market penetration. While increased operating losses are expected during the initial commercialization phase, this is a typical investment for a product launch with such a significant unmet need. The current cash position, along with the ATM facility, provides sufficient runway. The long-term growth prospects and competitive advantage of an oral therapy in a market dominated by injectables make this an attractive investment despite the near-term losses.

Keywords

KalVista Pharmaceuticals, EKTERLY, sebetralstat, Hereditary Angioedema, HAE, Oral Therapy, FDA Approval, Biopharmaceutical, Rare Diseases, Plasma Kallikrein Inhibitor, Commercial Launch, Orphan Drug, Pharmaceuticals, Clinical Trials, KONFIDENT, Royalty Financing, Drug Development, Market Exclusivity